BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

 BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

Shots:

  • BeiGene and Asieris collaborate to evaluate the safety and efficacy of APL-1202 + tislelizumab as neoadjuvant therapy in patients with MIBC. APL-1202 has been approved to treat patients with locally advanced or metastatic UC and high expression of PD-L1 who failed to receive platinum-based CT
  • Asieris plans to submit INDs in China and the US for P- I/II clinical study and determine the RP2D (recommended P-II dose)
  • APL-1202 is an orally reversible MetAP2 Inhibitor with anti-angiogenic, anti-tumor activities, currently in P- III clinical trials in China as monthx for the 1L treatment of non-muscle invasive for the 2L treatment of NMIBC

Click here to­ read full press release/ article | Ref: PRNewswire | Image: BeiGene

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post